Form 4: Prelude Therapeutics CEO Acquires Shares in Year-End Transaction

Prelude Therapeutics CEO, Krishna Vaddi, purchased 5,000 shares of common stock at $1.2087 per share on December 31, 2024.

Summary

• Krishna Vaddi, CEO of Prelude Therapeutics, acquired 5,000 shares of common stock on December 31, 2024, at a price of $1.2087 per share.
• Following this transaction, Mr. Vaddi directly owns 1,167,275 shares of Prelude Therapeutics common stock.
• He also has indirect beneficial ownership of 142,553 shares through Sidus Ventures LLC, 551,776 shares through the Blue Sky Trust, 551,774 shares through the Brocade Trust, and 423,655 shares through the Dolphin City Trust.
• Mr. Vaddi disclaims beneficial ownership of the indirectly held shares except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment, as it simply reports a transaction. The CEO's purchase could be interpreted as a positive sign, but it's not a major event.

Positives

• The CEO's purchase of shares could be seen as a positive signal of confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who trade their company's stock. It provides transparency into the trading activities of key personnel.

Comparison to Industry Standards

• SEC Form 4 filings are a standard practice for publicly traded companies in the United States.
• The level of detail provided in this filing is consistent with what is expected for insider trading disclosures.
• Similar filings are made by executives at comparable companies such as Mirati Therapeutics and Blueprint Medicines.

Stakeholder Impact

• The stock purchase may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Prelude Therapeutics, PRLD, insider trading, stock purchase, Krishna Vaddi, beneficial ownership, CEO